Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

Chang Chen et al.
  ChiCTR2000030254		 RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
120/120 inconclusive
  • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
Lou (FAVIPIRAVIR)
  ChiCTR2000029544		 RCTfavipiravir standard of careCOVID 19 all comerssome concern
10/10 inconclusive
  • inconclusive 82 % decrease in viral clearance ,viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
NCT04310228-FAVI (Zhao)
  ChiCTR2000030894		 RCTfavipiravir tocilizumab COVID 19 all comerssome concern
-/- inconclusive
  • inconclusive 68 % decrease in radiologic improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
4 studies excluded by filtering options (1 RCT / 3 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons